Kobo Biotech
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
The implementation of Kobo Biotech's court-approved resolution plan has been delayed past the 10 July 2026 deadline, the company said on 14 July. The NCLT Hyderabad had approved the plan submitted by Beaufond Industries on 11 May, requiring completion within sixty days. As of the disclosure date, the successful resolution applicant had not fulfilled the implementation terms. A meeting of the monitoring committee is being convened to decide the next steps.
Powered by Tijori
The implementation of Kobo Biotech's court-approved resolution plan has been delayed past the 10 July 2026 deadline, the company said on 14 July. The NCLT Hyderabad had approved the plan submitted by Beaufond Industries on 11 May, requiring completion within sixty days. As of the disclosure date, the successful resolution applicant had not fulfilled the implementation terms. A meeting of the monitoring committee is being convened to decide the next steps.
Powered by Tijori
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Kobo Biotech do?
Avon Organics Ltd specializes in producing Diketene, a fundamental component in various industries like pesticides, chemicals, pharmaceuticals, and dyestuffs. Their product range includes pharmaceutical, agrochemical, and pigment intermediates.
Who are the competitors of Kobo Biotech?
Kobo Biotech major competitors are Adeshwar Meditex, Hamps Bio, Unick Fix-A-Form, Cian Healthcare, Ishita Drugs & Inds., Rekvina Laboratories, Venmax Drugs&Pharma. Market Cap of Kobo Biotech is ₹23 Crs. While the median market cap of its peers are ₹22 Crs.
Is Kobo Biotech financially stable compared to its competitors?
Kobo Biotech seems to be less financially stable compared to its competitors. Altman Z score of Kobo Biotech is 0 and is ranked 6 out of its 8 competitors.
Does Kobo Biotech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Kobo Biotech latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Kobo Biotech allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Kobo Biotech balance sheet?
Kobo Biotech balance sheet is weak and might have solvency issues
Is the profitablity of Kobo Biotech improving?
The profit is oscillating. The profit of Kobo Biotech is -₹5.23 Crs for Mar 2025, -₹4.93 Crs for Mar 2024 and -₹5.55 Crs for Mar 2023
Is the debt of Kobo Biotech increasing or decreasing?
The net debt of Kobo Biotech is decreasing. Latest net debt of Kobo Biotech is ₹131 Crs as of Mar-25. This is less than Mar-24 when it was ₹139 Crs.
Is Kobo Biotech stock expensive?
There is insufficient historical data to gauge this. Latest PE of Kobo Biotech is 0
Has the share price of Kobo Biotech grown faster than its competition?
Kobo Biotech has given better returns compared to its competitors. Kobo Biotech has grown at ~230.55% over the last 1yrs while peers have grown at a median rate of -9.37%
Is the promoter bullish about Kobo Biotech?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Kobo Biotech is 44.95% and last quarter promoter holding is 44.95%.
Are mutual funds buying/selling Kobo Biotech?
There is Insufficient data to gauge this.